Publications by authors named "Hanneke Ter Burg"
Article Synopsis
- Current treatments for chronic lymphocytic leukemia (CLL) are not curative, prompting ongoing research for new therapies, particularly those involving JAK inhibitors, which have not been extensively studied in this context.
- JAK inhibitors like momelotinib and ruxolitinib were compared with other kinase inhibitors, revealing distinct effects on CLL cells and healthy immune cells, such as varying impacts on cytokine-induced proliferation and signaling pathways.
- Findings indicate that different kinase inhibitors can have unique effects on lymphocyte function, suggesting that a strategic approach could optimize therapy by balancing necessary lymphocyte inhibition while minimizing side effects.
